OMass Therapeutics Ltd.

https://www.omass.com

OMass Therapeutics is a biotechnology company discovering medicines against highly-validated target ecosystems, such as membrane proteins or intracellular complexes. OdyssION™, OMass’ unique drug discovery platform, comprises next-generation native mass spectrometry with novel biochemistry techniques and custom chemistry to interrogate not just a drug target, but also the interaction of the target with its native ecosystem, separate from the confounding complexity of the cell. This unique approach results in cell-system fidelity with cell-free precision. OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions. Its lead program is a best-in-class MC2 (melanocortin-2) receptor antagonist for the treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-dependent Cushing syndrome. The focus of the program has been to increase receptor residency time to make OMass’ antagonists resistant to competition by the endogenous ligand, thereby avoiding loss of efficacy in the face of rising adrenocorticotropic hormone (ACTH) levels due to reductions in glucocorticoid supplementation for CAH or progression of Cushing’s Syndrome. Headquartered in Oxford, UK, OMass has raised over $160M (£129M) from a top-tier international investor syndicate including Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures and British Patient Capital. *

	Start	2018-11-21 renamed
	Predecessor	OMass Technologies Ltd.
	Industry	drug discovery
	Industry 2	OdyssION™ technology platform
	Person	Deegan, Rosamond (Ros) (OMass Therapeutics 201905– CEO before Bicycle Therapeutics + Trevena + GSK)
	Person 2	Robinson, Carol (Univ Oxford 201004 Physical and Theoretical Chemistry Laboratory + OMass)

	Region	Oxford, Oxfordshire
	Country	United Kingdom (GB)
	Street	Heatley Road Oxford Science Park, The Schrödinger Building
	City	OX4 4GE Oxford, Oxfordshire
	Tel	+44-1865-548350
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: OMass Therapeutics Ltd.. (9/2/25). "Press Release: OMass Therapeutics Enters into Exclusive Collaboration and License Agreement with Genentech to Develop and Commercialize Therapies for Inflammatory Bowel Disease". Oxford.

		Record changed: 2026-05-02